6H-噻吩并[2,3-b]吡咯-5-羧酸 、 1,4-二氮杂双环[4.3.0]壬烷 以to provide the title compound (34 mg, 35%) as a light yellow solid的产率得到(hexahydro-pyrrolo[1,2-a]pyrazin-2-yl)-(6H-thieno[2,3-b]pyrrol-5-yl)-methanone
Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H
4
receptor, including allergic rhinitis.
Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders
申请人:Desmadryl Gilles
公开号:US20120039913A1
公开(公告)日:2012-02-16
The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.
SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS
申请人:INSERM (Institut National de la Santé
et de la Recherche Médicale)
公开号:EP3130376A1
公开(公告)日:2017-02-15
The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.
Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
申请人:INSERM (Institut National de la Sante de la Recherche Medicale)
公开号:US10195195B2
公开(公告)日:2019-02-05
The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.